Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Kidney Int. 2020 Dec 24;100(1):196–205. doi: 10.1016/j.kint.2020.12.015

Figure 4: Rejection rate and tumor response of melanoma subgroup.

Figure 4:

Allograft rejection rate (A) and objective response rate (ORR, B), stratified by the number of immunosuppressants. In ICI group, cancer response in 2 patients were undetermined and excluded from the analysis of ORR. In panel B, Anti-PD-1 indicates ORR of patients who received pembrolizumab or nivolumab monotherapy.